Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: A multicentric study

Vascular Health and Risk Management

Volumn 2, Issue 1, 2006, Pages 87-93

  Sharma, Manoj ^a   Sharma, Deepika R ^a   Singh, Vikram ^a   Panwar, R B ^b   Hira, H S ^c   Mohan, Bishav ^d   Kumar, Naveen ^d   Sharma, S K ^e   Gupta, Rajeev ^f  

^a Panacea Biotec Ltd   (India)

^b S P MEDICAL COLLEGE   (India)

^c MAULANA AZAD MEDICAL COLLEGE   (India)

^d DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^e SMS MEDICAL COLLEGE   (India)

^f Monilek Hospital   (India)

Author keywords

Coronary heart deisease; Hypercholesterolemia; Lipid abnormalities; Lipoprotein(a); Low HDL; South Asians

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOTRETINOIN; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NICOTINIC ACID; PYRROLE DERIVATIVE; THYROXINE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INDIAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; MYOPATHY; NAUSEA; OPEN STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDIA; LIPOPROTEIN(A); LOVASTATIN; MALE; MIDDLE AGED; NIACIN; TIME FACTORS; TRIGLYCERIDES;

EID: 33646072150     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.1.87     Document Type: Article

References (34)

1. Bhargava S. 2004. Evaluation of efficacy of non-drug therapy (dietary) and drug therapy in hypercholesterolemic subjects. MSc Dissertation. Jaipur: University of Rajasthan.
2. Bhatnagar D. 1998. The metabolic basis of increased coronary risk attributed to people from the Indian subcontinent. Current Science, 74:1087-94.
3. Botorrof MB. 2004. Statin safety: what to know. Am J Geriatr Cardiol, 13:34-8.
4. Cannon CP, Braunwald E, McCabe C, et al. 2004. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction-22 investigators (PROVE-IT TIMI-22). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 350:1495-504.
5. Chong PH, Bachenheimer BS. 2000. Current, new and future treatments in dyslipidemia and atherosclerosis. Drugs, 60:55-93.
6. Davignon J, Roederer G, Montigny M, et al. 1994. Comparative efficacy and safety of pravastatin, nicotinic acid and two combined in patients with hypercholesterolemia. Am J Cardiol, 73:339-45.
7. Deedwania PC, Hunninghake DB, Bays H. 2004. Effects of lipid altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol, 93(Suppl): 18C-26C.
8. Deedwania PC, Gupta R. 2005. East Asians and South Asians, and Asian and Pacific Islander Americans. In Wong ND, Black HR, Gardin JM (ed). Preventive Cardiology. 2nd Edition. New York: McGraw Hill. p 456-72.
9. Dhanjal TS, Lal M, Haynes R, Lip G. 2001. A comparison of cardiovascular risk factors among Indo-Asian and Caucasian patients admitted with acute myocardial infarction in Kuala Lumpur, Malaysia and Birmingham, England. Int J Clin Pract, 55:665-8.
10. Grundy SM. 2004. Obesity, metabolic syndrome and cardiovascular disease. J Clin Endocrinol Metab, 89:2595-600.
11. Grundy SM, Cleeman N, Bairey-Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110:227-39.
12. Gupta EK, Ito MK. 2002. Lovastatin and extended-release niacin combination product: The first drug combination for the management of hyperlipidemia. Heart Disease, 4:124-37.
13. Gupta R. 2000. Preventing coronary heart disease in India: focus on primary prevention. J Indian Med Assoc, 98:703-9.
14. Gupta R, Kaul V, Prakash H, et al. 2001. Lipid abnormalities in coronary heart disease: a population based case-control study. Indian Heart J, 53:332-36.
15. Guyton JR, Goldberg CA, Kreisberg RA, et al. 1998. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol, 82:737-43.
16. Henkin Y, Oberman A, Hurst DC, et al. 1991. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med, 91:239-46.
17. Illingworth DR, Bacon S. 1989. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Atherosclerosis, 9(Suppl 1): 1121-34.
18. Jones PH. 2004. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J, 148: S9-S13.
19. Kashyap ML, McGovern ME, Berra K, et al (2002). Long term safety and efficacy of a once daily niacin-lovastatin formulation for patients with dyslipidemia. Am J Cardiol, 89:672-78.
20. Kumar M, Chakravarti RN, Singh A, et al. 1976. Serum lipid profiles in patients of myocardial infarction in Chandigarh area (Northern India). Atherosclerosis, 24:355-61.
21. Kumar P, Luthra K, Dwivedi M, et al. 2003. Apolipoprotein E gene polymorphism in patients with premature myocardial infarction: a case-control study in northem Asian Indians. Ann Clin Biochem, 40:382-6.
22. Luthra K, Bhargava B, Chhabra S, et al. 2002. Apolipoprotein E polymorphism in northern Indian patients with coronary heart disease: phenotype distribution and relation to serum lipids and lipoproteins. Mol Cell Biochem, 232:97-102.
23. [NCEP] National Cholesterol Education Program. 2002. Third report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP-III) final report. Circulation, 106:3143-421.
24. O'Keefe JH, Harris WS, Nelson J, et al. 1995. Effects of pravastatin with niacin or magnesium on lipid levels ans postprandial lipemia. Am J Cardiol, 6:480-4.
25. Pais P, Pogue S, Gerstein H, et al. 1996. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet, 348:358-63.
26. Panacea-Biotec. 2004. Niacin extended release tablet pharmacokinetics. Data on file.
27. Pasternak RC, Smith SC, Bairey-Merz CN, et al. 2002. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 40:567-72.
28. Sahi N, Pahlajani DB, Sainani GS. 1993. Apolipoproteins A1 and B as predictors of angiographically assessed coronary artery disease. J Assoc Physicians India, 41:713-15.
29. Thompson GR. 2004. Combination therapy with statins. In: Gaw A, Packard CJ, Shepherd J. Editors. Statins. 2nd edition. London: Martin Dunitz. p 189-99.
30. Vacek JL, Dittmeir G, Chiarelli T, et al. 1995. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoprotenemia. Am J Cardiol, 76:182-4.
31. Vashist S, Narula J, Awtade A, et al. 1990. Lipids and lipoproteins in normal controls and clinically documented coronary heart disease patients. Ann Natl Acad Med Sci (India), 26:57-66.
32. Warnica JW. 2004. The CARE trial: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. In Gaw A, Packard CJ, Shepherd J (ed). Statins. 2nd edition. London: Martin Dunitz. p 123-43.
33. Wasir HS, Bharani A, Bhatia ML. 1987. Correlation of risk factors with coronary angiographic findings in patients of ischemic heart disease. J Assoc Physicians India, 35:483-7.
34. Wolfe ML, Vartianen SF, Ross JL, et al. 2001. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol, 87:476-9.